Literature DB >> 16450371

Nuclear targeting of a midregion PTHrP fragment is necessary for stimulating growth in breast cancer cells.

Rajendra Kumari1, John F Robertson, Sue A Watson.   

Abstract

Parathyroid-hormone related protein (PTHrP) is the primary factor in humoral hypercalcemia of malignancy and is highly secreted by breast cancers. The pro-hormone undergoes post-translational processing and cleavage to give rise to mature secretory peptides, one of which is midregion PTHrP (38-94/95/101) containing a nuclear localisation sequence (NLS) in amino acids (87-106). The current study investigates whether the NLS in midregion PTHrP is important in breast cancer growth. PTHrP-(67-101), a midregion PTHrP fragment containing NLS-(87-101) significantly increased growth of MCF-7 and MDA-MB231 cells (126.3 and 121.3% of control respectively in serum conditions), independent of PTHR1 whereas PTHrP-(67-86), which lacks the NLS did not. Fluorescent-labelled PTHrP-(67-101) translocated to the nucleus, whereas PTHrP-(67-86) remained cytosolic and a scrambled(+NLS) peptide was not internalised. In comparison, no growth influence or uptake was seen in non-tumour breast cells (Hs578Bst). Increases in intracellular calcium mobilisation were observed in breast cancer cells stimulated with both PTHrP-(67-101) and PTHrP-(67-86) (EC(50) of 3.2 pM and 2.2 pM respectively for MCF-7 cells), whereas inositide turnover was not detected. Both nuclear uptake and calcium signalling were attenuated in the presence of EGTA, but not with U73122 or N-terminal PTHrP peptides. Our studies indicate that the NLS-containing midregion PTHrP peptide is dependent on both internalisation and nuclear translocation to induce growth in breast cancer cells. These findings highlight the importance of midregion PTHrP and its receptor in breast cancer growth and may provide potential targets for future therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16450371     DOI: 10.1002/ijc.21802

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

Review 1.  Lessons from in vitro studies and a related intracellular angiotensin II transgenic mouse model.

Authors:  Julia L Cook; Richard N Re
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

2.  PTHrP inhibits BMP-6 expression through the PKA signaling pathway in breast cancer cells.

Authors:  Dong Mi; Ming Zhang; Ji-dong Yan; Jie Zhang; Xu Wang; Qing Wang; Shuang Yang; Tian-hui Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-18       Impact factor: 4.553

3.  Parathyroid hormone-related peptide and parathyroid hormone-related peptide receptor type 1 in locally advanced laryngeal cancer as prognostic indicators of relapse and survival.

Authors:  Giovanni Almadori; Antonella Coli; Eugenio De Corso; Dario Antonio Mele; Stefano Settimi; Giovanni Di Cintio; Francesca Brigato; Domenico Scannone; Libero Lauriola; Franco Oreste Ranelletti
Journal:  BMC Cancer       Date:  2022-06-27       Impact factor: 4.638

4.  Endothelin-1 (ET-1) increases the expression of remodeling genes in vascular smooth muscle through linked calcium and cAMP pathways: role of a phospholipase A(2)(cPLA(2))/cyclooxygenase-2 (COX-2)/prostacyclin receptor-dependent autocrine loop.

Authors:  Karl Deacon; Alan J Knox
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

5.  Nuclear trafficking of secreted factors and cell-surface receptors: new pathways to regulate cell proliferation and differentiation, and involvement in cancers.

Authors:  Nathalie Planque
Journal:  Cell Commun Signal       Date:  2006-10-18       Impact factor: 5.712

6.  Absence of PTHrP nuclear localization and carboxyl terminus sequences leads to abnormal brain development and function.

Authors:  Zhen Gu; Yahong Liu; Yongjie Zhang; Shulei Jin; Qi Chen; David Goltzman; Andrew Karaplis; Dengshun Miao
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.